Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., and Endo Pharmaceuticals, have received U.S. FDA acceptance of the IND filing for a novel molecule targeting prostate cancer, which is anticipated to enter clinical trials in late 2013. The multi-target oncology collaboration entered four years ago, is focused on developing differentiated therapies that address the unmet needs of cancer patients worldwide. To date the collaboration has delivered on multiple discovery milestones.
"We are very pleased and elated with this successful outcome, which is the result of excellent collaboration between the scientists at Endo and Jubilant Biosys. Being at the forefront of pharmaceutical, life sciences and healthcare innovation, Jubilant pursues its goal to enable affordable healthcare to patients worldwide," said Dr. Subir Kumar Basak, president, Global Drug Discovery Services, Jubilant Life Sciences.
Dr. Sandeep Gupta, senior vice president, Discovery & Early Development, Endo Pharmaceuticals, said, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled the successful filing and acceptance of an IND in less than three years. The IND filing and progression of the molecule to the next stage of development further validates Endo's unique collaborative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."